Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × B-cell Malignancies × zanubrutinib × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5 Lymphoma, Mantle-Cell 4 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Hematologic Diseases 1 B-cell Malignancies 1

Interventions

zanubrutinib 1 tislelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

BeOne Medicines

Phase 3 Active not recruiting

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡